Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Blood|August 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsDelphine Réa, Michael J Mauro, Carla Boquimpani, et al.
Leukemia|January 30, 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLAndreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
Leukemia|July 16, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final resultsJorge E Cortes, Delphine Rea, Michael J Mauro, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Pageof 23